SCHEMBL1542748

SCHEMBL1542748

COc1c(NC(=O)c2ccc(N)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.47
BTK Q06187 1/20 0.43
KIT P10721 1/20 0.40
SRC P12931 1/20 0.40
FLT3 P36888 1/20 0.40
ITK Q08881 1/20 0.40
MAPT P10636 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
TP53 P04637 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.39
ABL1 P00519 1/20 0.39
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HDAC1 Q13547 2/20 0.38
NR1H4 Q96RI1 2/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542657 0.91 CYP3A4 (0.49) CYP3A4BTKKITSRCFLT3
SCHEMBL1542627 0.89 CYP3A4 (0.44) CYP3A4BTKKITSRCFLT3
SCHEMBL2128418 0.89 CYP3A4 (0.49) CYP3A4BTKKITSRCFLT3
SCHEMBL1543460 0.88 CYP3A4 (0.44) CYP3A4BTKKITSRCFLT3
SCHEMBL1542931 0.88 CYP3A4 (0.44) CYP3A4BTKKITSRCFLT3
SCHEMBL1542928 0.87 CYP3A4 (0.44) CYP3A4BTKKITSRCFLT3
SCHEMBL1542369 0.86 CYP3A4 (0.65) CYP3A4BTKMAPTSMN1; SMN2TP53
SCHEMBL1542476 0.86 CYP3A4 (0.44) CYP3A4BTKMAPTTP53ABL1
SCHEMBL2127468 0.86 CYP3A4 (0.44) CYP3A4MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL1542911 0.86 CYP3A4 (0.49) CYP3A4BTKKITSRCFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885BTK 2299/4885KIT 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.